STOCK TITAN
  1. Home
  2. Sec-filings
  3. MGTX
  4. [Form 4] MeiraGTx Holdings plc Insider Trading Activity

MeiraGTx (MGTX) chief scientist sells 27,659 shares in pre-set 10b5-1 trades

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MeiraGTx Holdings plc chief scientific officer for ophthalmology Stuart Naylor sold 27,659 ordinary shares of the company in open-market transactions. The sales occurred on July 7, 2026 at weighted average prices reported around $13.36 to $15.33 per share across multiple trades.

Following these transactions, Naylor directly holds 640,846 ordinary shares of MeiraGTx. The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the trades were scheduled in advance rather than timed opportunistically.

Positive

  • None.

Negative

  • None.
Insider Naylor Stuart
Role CHIEF SCI OFCR, OPHTHALMOLOGY
Sold 27,659 shs ($409K)
Type Security Shares Price Value
Sale Ordinary Shares 2,547 $13.86 $35K
Sale Ordinary Shares 25,112 $14.90 $374K
Holdings After Transaction: Ordinary Shares — 665,958 shares (Direct, null)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2025. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.36 to $14.31, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.47 to $15.33, inclusive.
Shares sold 27,659 shares Total ordinary shares sold on July 7, 2026
Sale price range (block 1) $13.36–$14.31 per share Weighted-average sales price range for one group of trades
Sale price range (block 2) $14.47–$15.33 per share Weighted-average sales price range for another group of trades
Shares held after transactions 640,846 shares Direct ordinary share holdings following July 7, 2026 sales
10b5-1 plan adoption date December 9, 2025 Date Naylor adopted the Rule 10b5-1 trading plan
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sales price financial
"The price reported reflects the weighted average sales price. The shares were sold in multiple transactions..."
open-market sale financial
"transaction_action: open-market sale"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
ordinary shares financial
"security_title: Ordinary Shares"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider transaction did MeiraGTx (MGTX) report for Stuart Naylor?
MeiraGTx reported that chief scientific officer for ophthalmology Stuart Naylor sold 27,659 ordinary shares in open-market transactions. These trades were executed on July 7, 2026, at weighted average prices in the mid-teens per share across multiple individual sales.

At what prices did Stuart Naylor sell MeiraGTx (MGTX) shares?
The filing states the reported prices are weighted averages from multiple trades. One group of sales ranged from $13.36 to $14.31 per share, and another from $14.47 to $15.33 per share, reflecting execution across a price range rather than a single trade price.

How many MeiraGTx (MGTX) shares does Stuart Naylor hold after the sale?
After the reported transactions, Stuart Naylor directly holds 640,846 ordinary shares of MeiraGTx. This post-transaction holding figure comes from the Form 4 and shows he retains a substantial equity position in the company following the July 7, 2026 sales.

Were Stuart Naylor’s MeiraGTx (MGTX) share sales under a Rule 10b5-1 plan?
Yes. The filing specifies that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Such plans pre-schedule trades, indicating these sales were arranged in advance rather than made on a discretionary, real-time basis.

How many MeiraGTx (MGTX) shares did Stuart Naylor sell in total?
According to the transaction summary, Stuart Naylor sold a total of 27,659 ordinary shares. This total reflects two reported open-market sale transactions on July 7, 2026 and is categorized in the filing as net-sell activity with no corresponding purchases.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Naylor Stuart
(Last)(First)(Middle)
655 THIRD AVENUE
SUITE 1115
(Street)
NEW YORK NEW YORK 10017
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MeiraGTx Holdings plc [ MGTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF SCI OFCR, OPHTHALMOLOGY
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares07/07/2026S(1)2,547D$13.86(2)(3)665,958D
Ordinary Shares07/07/2026S(1)25,112D$14.9(3)(4)640,846D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 9, 2025.
2. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.36 to $14.31, inclusive.
3. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
4. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $14.47 to $15.33, inclusive.
/s/ Richard Giroux, Attorney-in-fact for Stuart Naylor07/07/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR